Hospira
 
2Q Revenues: $1.0 billion (-3%)

2Q Loss: $2.5 million (earnings were $143.6 million 2Q11)

YTD Revenues: $2.0 billion (-3%)

YTD Earnings: $37.8 million (earnings were $293.5 million YTD11)

Comments: Specialty Injectable Pharmaceuticals revenue was $644.2 million (-5%). Medication Management revenue was $255.1 million (+4%). Other Pharma revenues, which includes contract manufacturing services, were down 6% to $134.0 million. Restructuring costs were $32.2 million in the quarter compared to $1.5 million in 2Q11, with facilities optimization charges of $17.4 million.